Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.

J J FerreiraA LeesJosé-Francisco RochaW PoeweO RascolP Soares-da-Silva

Published in: European journal of neurology (2019)

Over at least 1 year of open-label therapy, opicapone consistently reduced OFF time and increased ON time without increasing the frequency of troublesome dyskinesia.

Keyphrases

open label
clinical trial
phase iii
end stage renal disease
phase ii
ejection fraction
chronic kidney disease
phase ii study
study protocol
peritoneal dialysis
squamous cell carcinoma
prognostic factors
randomized controlled trial
mesenchymal stem cells
bone marrow
double blind
artificial intelligence
cell therapy